核酸适配体在心血管疾病诊疗中的应用及研究进展  

Application and research progress of aptamers in the diagnosis and treatment of cardiovascular diseases

作　　者：李明 雷涛 邢平川 王志军 LI Ming;LEI Tao;XING Pingchuan;WANG Zhijun(Department of Cardiology,The Affiliated Hospital of North China University of Science and Technology,Tangshan 063000,China)

机构地区：[1]华北理工大学附属医院心内科,河北唐山063000

出　　处：《华北理工大学学报（医学版）》2024年第6期499-504,共6页Journal of North China University of Science and Technology：Health Sciences Edition

基　　金：河北省卫健委医学重点科研项目(编号:ZF2024198)。

摘　　要：心血管疾病(CVD)是全球主要致死性疾病之一[1],严重危害人类健康。核酸适配体具有高特异性与高亲和力,可高效检测多种生物标志物,提供高灵敏度和高特异性的诊断结果。在心血管疾病的诊治中核酸适配体对心肌肌钙蛋白、B型利钠肽等生物标志物具有高灵敏度和特异性的检测价值。同时作为靶向抑制剂,核酸适配体通过精准靶向心血管疾病相关分子如凝血因子和血小板蛋白、骨桥蛋白、前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)等而发挥治疗作用。随着分子生物学技术的进步,核酸适配体的筛选、合成及修饰技术持续优化,将进一步推动其在临床中的应用。Cardiovascular diseases(CVDs)are one of the leading causes of death worldwide[1],posing a serious threat to human health.Aptamers,characterized by high specificity and affinity,can efficiently detect a variety of biomarkers,providing diagnostic results with high sensitivity and specificity.In the diagnosis and treatment of CVDs,aptamers exhibit high sensitivity and specificity in detecting biomarkers such as troponin and B-type natriuretic peptide.Meanwhile,as targeted inhibitors,aptamers exert therapeutic effects by precisely targeting CVD-related molecules such as coagulation factors,platelet proteins,osteopontin,and proprotein convertase subtilisin/kexin type 9(PCSK9).With advancements in molecular biology technology,the screening,synthesis,and modification techniques of aptamers continue to be optimized,further promoting their clinical applications.

关 键 词：核酸适配体 心血管疾病 生物标志物 骨桥蛋白 

分 类 号：R446[医药卫生—诊断学]